These 2 Early-Stage COVID Vaccines Might Be Game-Changers

All eyes are on the leading late-stage COVID-19 vaccine prospects today. Nevertheless, there are other speculative vaccines in advancement that might likewise be on the method. In this Motley Fool Live video tape-recorded on Dec. 3, 2020, Health Care and Cannabis Bureau Chief Corinne Cardina and author Keith Speights go over 2 early-stage COVID vaccines that might be game-changers.

[embedded content]

Corinne Cardina: Exist any drug designers that might be earlier phases than a few of the ones we’ve discussed that are taking a technique that could be game-changing?

Keith Speights: Yeah, there are a couple that I have actually actually enjoyed, Corinne.

One I believe you and I have actually discussed previously– Vaxart ( NASDAQ: VXRT) Vaxart has an early-stage oral tablet. The concept of having a vaccine that you simply pop a tablet, so to speak, rather of getting stuck to a needle, that would be rather interesting. Really low market cap there– listed below $1 billion. Once again, it’s early phase, however if they succeed, Vaxart might actually remove.

Another one, a little plug here, an outrageous plug. I’m dealing with a post that must release on Saturday. It has to do with the dark horse to enjoy, which dark horse to enjoy in the coronavirus vaccine race, I believe, is Arcturus Therapies ( NASDAQ: ARCT)

Arcuturs has an mRNA vaccine. Pfizer and Moderna have mRNA vaccines, so we have actually currently seen that they can have a truly high effectiveness. However they have an mRNA single-dose vaccine that remains in a stage 1/2 research study.

They likewise wish to have a freeze-dried variation of it readily available for stage 3 screening. You have actually got Arcturus with simply marking off all packages. Single-dose, which will be fantastic, mRNA, which appears to have really high effectiveness, and freeze-dried, which would attend to a few of the ultra-cold storage requirements. Arcturus is one that I actually am amazed by. I’m visiting what occurs next and see how the outcomes look.

Corinne Cardina: Keith, do you understand the ticker for Arcturus?

Keith Speights: Yeah. That’s ARCT.

Corinne Cardina: Got it.

Keith Speights: Once again, the very best method to explain Arcturus is a dark horse. They might actually come on strong if things work out.

Latest posts